Evaluation of Flexofytol® PLUS in Hand Joint Chronic Dyscomfort.

NCT ID: NCT05089318

Last Updated: 2023-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

239 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-01

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of curcuminoids and Boswellia serrata extracts combination (Flexofytol PLUS) in support to standard treatments during a 12-weeks period on hand pain on people with chronic hand joint discomfort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hand Joint Discomfort

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flexofytol PLUS

2 tablets in the morning and in the evening for minimum 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Older dan 45 years old,
* With hand joint chronic discomfort,
* Regularly uses of paracetamol or NSAIDs to manage pain,
* Painful symptoms must have been present for more than 6 months,
* The patient assesses their pain on a visual pain scale and must be greater than 4 out of 10 over the last 48 hours.

Exclusion Criteria

* Related to previous and associated treatments:

* Corticosteroids injection in the 3 previous months, whatever the joint concerned,
* Use of Slow-acting drugs for OA and/or dietary supplements taken within less than 6 months prior to the study (ex: chondroitin sulfate, diacerein, soy and avocado unsaponifiables, oxaceprol, granions de cuivre, glucosamine, phytotherapy or homeopathy for hand joint discomfort..),
* Anticoagulant (coumarinic) treatment and heparin,
* General corticotherapy in the 3 previous months,
* Contraindication to paracetamol, curcumin, boswellia and NSAID's.
* Related to associated pathologies:

* Patient suffering from serious associated illness (liver failure, kidney failure, non-controlled cardiovascular diseases...),
* The patient has rheumatoid arthritis or gout,
* The patient has a bile obstruction.
* Related to patient:

* Pregnant or breastfeeding women.
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tilman S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yvan Dierckxsens

Role: STUDY_DIRECTOR

Tilman S.A.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yves Henrotin

Boncelles, Liège, Belgium

Site Status

Yves Henrotin

Boncelles, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FLEXOPAM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.